Immuta Announces $90 Million in Series D Funding
20.5.2021 16:00:00 EEST | Business Wire | Press release
Immuta, the leading provider of cloud data access control, today announced that it has secured $90 million in Series D funding. Immuta will use the investment to further its market leadership position and capture rising demand for centralized, scalable access control across cloud data sets that are increasingly diverse and distributed on multiple compute platforms. The new investment comes less than a year after Immuta’s Series C investment and brings total capital raised to $169 million.
The Series D funding round includes new investors Greenspring Associates, March Capital, NGP Capital, and Wipro Ventures, as well as participation from existing investors Ten Eleven Ventures, Intel Capital, DFJ Growth, Dell Technologies Capital, Citi Ventures, and Okta Ventures. The investment will go towards accelerating Immuta’s product research and development, expanding sales and marketing capacity to capture growing demand in the U.S., EMEA, and APAC, and deepening strategic partnerships within the cloud data ecosystem. Amazon Redshift and Azure Synapse are the latest cloud data platforms to be integrated with Immuta’s platform as part of its latest release announced today.
“We’ve entered a new era in data and analytics fueled by ubiquitous cloud storage, new cloud data management tools, and the rise of DataOps,” said Immuta’s CEO Matthew Carroll. “In this new environment, data teams are challenged to provide secure, scaled access to thousands of cloud data products while maintaining strong security, privacy protection, and auditability. Traditional methods of data access control don’t work, don’t scale across cloud compute platforms, and can limit data utility. Immuta’s platform solves this problem elegantly without requiring data to be moved, copied, or manually provisioned. This new funding will accelerate innovation and GTM expansion so we can deliver our platform to more customers as we lead the charge to define the future of cloud data access control.”
“We looked at other competition in the space and Immuta’s product and solutions are really at the top of the heap,” said Hunter Somerville, General Partner at Greenspring Associates. “From intelligent data discovery, to data access and control, to integration with all the top cloud analytics services, Immuta’s platform is best-in-class. We also liked that Immuta prioritized the data architecture and engineering team, from an end-sales standpoint, which we didn't see from other solutions in the space.”
“We invest in tomorrow’s winners,” said Jed Leidheiser, Partner at March Capital. “I look for companies that have tremendous customer satisfaction today, with architectures built for platform expansion, and an A+ team to execute. That’s Immuta. They have the ability to operate on any data source, any infrastructure, any cloud platform — and on top of that, their customer list is rapidly growing.”
Since its founding in 2015, Immuta has built strategic partnerships with the leading cloud data technology providers and enhanced its platform to provide a single place for data teams to automate data across control across their entire cloud infrastructure. As the market leader, Immuta helps large enterprises scale centralized data operations and analytics teams and helps innovative technology companies build and scale data-powered apps and services. In its last fiscal year, Immuta grew worldwide bookings by more than 115%, doubled its full-time headcount, and expanded its global base of customers including Aon, Credit Suisse, Daimler, Flatiron, IAG, S&P Global, and US Army.
"Immuta has been a longtime partner of Databricks and we are excited to see this impressive round of funding. We look forward to helping bring their cloud data access control capabilities to more joint customers as they're building their future data and analytics stack on the lakehouse platform," said Ali Ghodsi, CEO and co-founder of Databricks.
“One of the really big advantages that Immuta has given us, from a return-on-investment perspective, is our ability to make change happen faster,” said Dave Abrahams, Executive
General Manager of Data, IAG, one of Australia and New Zealand’s largest general insurance providers and an Immuta investor. “Previously, it would take months of manual assessments, and working through the challenges around how we could access and use data to help create the best products for our customers. We are now able to do that in an instant, globally, across all of our data.”
For more information about Immuta, visit www.immuta.com. Join the Immuta conversation on LinkedIn and Twitter.
About Immuta
Immuta is the market leader in cloud data access control, providing data engineering and operations teams one universal platform to control access to analytical data sets in the cloud. Only Immuta can automate access control for any data, on any cloud service, across all compute infrastructure. Data-driven organizations around the world rely on Immuta to speed time to data, safely share more data with more users, and mitigate the risk of data leaks and breaches. Founded in 2015, Immuta is headquartered in Boston, MA. Learn more at www.immuta.com.
About Greenspring
Greenspring Associates was founded in 2000 to focus solely on venture capital investments. Through a comprehensive platform, the Firm serves as a lifecycle partner for fund managers and entrepreneurs, investing across multiple stages, sectors and geographies. Greenspring Associates currently manages over $12 billion in committed capital across a variety of specialized venture strategies on behalf of a diverse group of global investors. For more information on Greenspring Associates, please visit its website at www.greenspringassociates.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005254/en/
Contact information
Joe Madden, joe.madden@immuta.com
Ryan Schin, Immuta@matternow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 14:20:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 14:15:00 EEST | Press release
Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined by much of the institutional investment community. Xsolla's presence at SuperReturn International reflects a broader moment: the convergence of a mu
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
